Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma

Over 90% of head and neck squamous cell carcinoma (HNSCC) overexpresses the epidermal growth factor receptor (EGFR). However, the EGFR-targeted monotherapy response rate only achieves 10–30% in HNSCC. Recombinant immunotoxin (RIT) often consists of an antibody targeting a tumor antigen and a toxin (...

Full description

Bibliographic Details
Main Authors:	Guiqin Xie, Liang Shan, Yuanyi Liu, Tzyy-Choou Wu, Xinbin Gu
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Biology
Subjects:	head and neck squamous cell carcinoma HNSCC EGFR recombinant immunotoxin efficacy
Online Access:	https://www.mdpi.com/2079-7737/11/4/486

Similar Items

Optimization of Chemically Defined Cell Culture Media for Recombinant ONTAK Immunotoxin Production
by: Mohammad Heydari, et al.
Published: (2014-10-01)

Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells
by: Khalil Hajiasgharzadeh, et al.
Published: (2021-07-01)

<i>EGFR</i> Mutations in Head and Neck Squamous Cell Carcinoma
by: Sindhu Nair, et al.
Published: (2022-03-01)

Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Bhamini Patel, et al.
Published: (2021-07-01)

Study of the association of the known prognostic variables with EGFR expression in head and neck squamous cell carcinomas
by: Toyaja Jadhav, et al.
Published: (2024-01-01)

Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma
by: Ching-Yun Hsieh, et al.
Published: (2023-10-01)

Head and neck malignant lymphoma and squamous cell carcinoma discernment, is DWI conclusive?
by: Dina Gameel Anis, et al.
Published: (2023-12-01)

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma
by: Guiqin Xie, et al.
Published: (2023-10-01)

Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation
by: Erik Haehl, et al.
Published: (2022-11-01)

Cloning and Expression of Ontak Immunotoxin Using Intein Tag
by: SA Moosavizadeh, et al.
Published: (2016-06-01)

The Role of Inflammation-Associated Factors in Head and Neck Squamous Cell Carcinoma
by: Li K, et al.
Published: (2023-09-01)

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
by: Shengjin Dou, et al.
Published: (2022-03-01)

A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
by: Zeng Qi, et al.
Published: (2021-04-01)

Clinical presentation and pattern of care for sarcomatoid variant of squamous cell carcinoma of the head-and-neck region: A retrospective study
by: Adhara Chakraborthy, et al.
Published: (2021-01-01)

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
by: Nathan Simon, et al.
Published: (2016-05-01)

Effects of Human Papilloma Virus E6/E7 Oncoproteins on Genomic Structure in Head and Neck Squamous Cell Carcinoma
by: Matthew Uzelac, et al.
Published: (2022-12-01)

HIF-1α or HOTTIP/CTCF Promotes Head and Neck Squamous Cell Carcinoma Progression and Drug Resistance by Targeting HOXA9
by: Qiang Sun, et al.
Published: (2020-06-01)

The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
by: Rin Liu, et al.
Published: (2021-12-01)

Development and validation of a nomogram to predict cervical lymph node metastasis in head and neck squamous cell carcinoma
by: Xiaohan Chen, et al.
Published: (2024-01-01)

Diagnostic and Therapeutic Applications of Exosomes in Cancer with a Special Focus on Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Eliane Ebnoether, et al.
Published: (2020-06-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
by: Brendan L. Hagerty, et al.
Published: (2020-06-01)

The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas
by: Nobuo Kondoh, et al.
Published: (2022-06-01)

Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma
by: Yangyang She, et al.
Published: (2020-01-01)

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
by: Habib Sadeghirad, et al.
Published: (2023-04-01)

Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications
by: Claudia Peitzsch, et al.
Published: (2019-05-01)

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma
by: José A. Peña-Flores, et al.
Published: (2022-08-01)

Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation
by: Maximilian Linxweiler, et al.
Published: (2023-12-01)

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression
by: Stefania Zuppone, et al.
Published: (2019-05-01)

Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma
by: Zhexuan Li, et al.
Published: (2020-02-01)

Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma
by: Madhavi Murali, et al.
Published: (2022-11-01)

Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma
by: Lauren C. J. Baker, et al.
Published: (2018-07-01)

A Ferroptosis-Related Gene Signature for Predicting the Prognosis and Drug Sensitivity of Head and Neck Squamous Cell Carcinoma
by: Wei Lu, et al.
Published: (2021-10-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma
by: Martin Morisse, et al.
Published: (2023-07-01)

A 14-Marker Multiplexed Imaging Panel for Prognostic Biomarkers and Tumor Heterogeneity in Head and Neck Squamous Cell Carcinoma
by: Junichi Mitsuda, et al.
Published: (2021-08-01)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
by: Sei-Yong Jun, et al.
Published: (2022-12-01)

Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2023 edition)
by: XU Tingting, HU Chaosu, LI Baosheng
Published: (2023-01-01)

Hypoxia-related LncRNAs signature predicts prognosis and is associated with immune infiltration and progress of head and neck squamous cell carcinoma
by: Minhan Li, et al.
Published: (2022-09-01)

Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment
by: Carmen Stromberger, et al.
Published: (2021-02-01)